Effect of statin therapy on vaspin levels in type 2 diabetic patients

Clinical Pharmacology: Advances and Applications

Volumn 5, Issue , 2013, Pages 33-38

  Al Azzam, Sayer I ^a   Alzoubi, Karem H ^a   Abeeleh, Jaafar Abu ^b   Mhaidat, Nizar M ^a   Abu Abeeleh, Mahmoud ^c  

^a JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

^b Royal Medical Services   (Jordan)

^c UNIVERSITY OF JORDAN   (Jordan)

Author keywords

Adipokines; Diabetes; Statins; Vaspin

Indexed keywords

CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL; VASPIN;

ADULT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84874380241     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S42496     Document Type: Article

References (29)

1. Kotlega D, Ciecwiez S, Turowska-Kowalska J, Nowacki P. Pathogenetic justification of statin use in ischaemic stroke prevention according to inflammatory theory in development of atherosclerosis. Neurol Neurochir Pol. 2012;46(2):176-183. Polish.
2. Wright RS, Murphy JG, Bybee KA, Kopecky SL, LaBlanche JM. Statin lipid-lowering therapy for acute myocardial infarction and unstable angina: efficacy and mechanism of benefit. Mayo Clin Proc. 2002;77(10):1085-1092.
3. Istvan ES. Structural mechanism for statin inhibition of 3-hydroxy-3methylglutaryl coenzyme A reductase. Am Heart J. 2002;144(Suppl 6): S27-S32.
4. Blanco-Colio LM, Tunon J, Martin-Ventura JL, Egido J. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int. 2003;63(1):12-23.
5. Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol. 2001;77(2-3):247-253.
6. Lyngdoh T, Vollenweider P, Waeber G, Marques-Vidal P. Association of statins with inflammatory cytokines: a population-based Colaus study. Atherosclerosis. 2011;219(1):253-258.
7. Sparrow C P, Burton CA, Hernandez M, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol. 2001; 21(1):115-121.
8. Naples M, Federico LM, Xu E, Nelken J, Adeli K. Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: evidence for statin-induced hepatic insulin sensitization. Atherosclerosis. 2008;198(1):94-103.
9. Furuya DT, Poletto AC, Favaro RR, Martins JO, Zorn TM, Machado U F. Anti-inflammatory effect of atorvastatin ameliorates insulin resistance in monosodium glutamate-treated obese mice. Metabolism. 2010;59(3):395-399.
10. Kalupahana NS, Moustaid-Moussa N. The renin-angiotensin system: a link between obesity, infammation and insulin resistance. Obes Rev. 2012;13(2):136-149.
11. Zeyda M, Stulnig TM. Obesity, infammation, and insulin resistance - a mini-review. Gerontology. 2009;55(4):379-386.
12. Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav. 2008;94(2):206-218.
13. Zhuang XF, Zhao MM, Weng CL, Sun NL. Adipocytokines: a bridge connecting obesity and insulin resistance. Med Hypotheses. 2009;73(6):981-985.
14. Kloting N, Berndt J, Kralisch S, et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun. 2006;339(1):430-436.
15. Kadoglou N P, Gkontopoulos A, Kapelouzou A, et al. Serum levels of vaspin and visfatin in patients with coronary artery disease - Kozani study. Clin Chim Acta. 2011;412(1-2):48-52.
16. Al-Azzam SI, Alzoubi KH, Khabour O, Alowidi A, Tawalbeh D. The prevalence and factors associated with aspirin resistance in patients premedicated with aspirin. Acta Cardiol. 2012;67(4):445-448.
17. Abeles AM, Pillinger MH. Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy? Arthritis Rheum. 2006;54(2):393-407.
18. Kadoglou N P, Vrabas IS, Kapelouzou A, et al. Impact of atorvastatin on serum vaspin levels in hypercholesterolemic patients with moderate cardiovascular risk. Regul Pept. 2011;170(1-3):57-61.
19. Zhou Q, Liao JK. Pleiotropic effects of statins. Basic research and clinical perspectives. Circ J. 2010;74(5):818-826.
20. Pedersen TR. Pleiotropic effects of statins: evidence against benefts beyond LDL-cholesterol lowering. Am J Cardiovasc Drugs. 2010; 10 Suppl 1:10-17.
21. Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A. 2005;102(30):10610-10615.
22. Doran AC, Meller N, McNamara CA. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28(5):812-819.
23. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340(2):115-126.
24. Phalitakul S, Okada M, Hara Y, Yamawaki H. Vaspin prevents TNF-alpha-induced intracellular adhesion molecule-1 via inhibiting reactive oxygen species-dependent NF-kappaB and PKCtheta activation in cultured rat vascular smooth muscle cells. Pharmacol Res. 2011;64(5):493-500.
25. Phalitakul S, Okada M, Hara Y, Yamawaki H. A novel adipocytokine, vaspin inhibits platelet-derived growth factor-BB-induced migration of vascular smooth muscle cells. Biochem Biophys Res Commun. 2012;423(4):844-849.
26. Kobat MA, Celik A, Balin M, et al. The investigation of serum vaspin level in atherosclerotic coronary artery disease. J Clin Med Res. 2012; 4(2):110-113.
27. Cantarini L, Simonini G, Fioravanti A, et al. Circulating levels of the adipokines vaspin and omentin in patients with juvenile idiopathic arthritis, and relation to disease activity. Clin Exp Rheumatol. 2011;29(6): 1044-1048.
28. Yilmaz Y, Kurt R, Gurdal A, et al. Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary fow reserve in patients with nonalcoholic fatty liver disease. Atherosclerosis. 2011;217(1):125-129.
29. Kukla M, Zwirska-Korczala K, Hartleb M, et al. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2010;45(2):235-242.